Core Viewpoint - The company held its third board meeting on December 26, 2025, where several important resolutions were passed, including adjustments to fundraising projects, the addition of implementation entities, and the establishment of a high-level compensation system [1] Group 1: Fundraising Project Adjustments - The board approved a proposal to extend the construction period for the "Information System Upgrade Project" and the "Medical Consumables Centralized Operation Service Project," optimizing the internal investment structure to enhance fundraising efficiency [2] - The addition of an implementation entity for the "Medical Consumables Centralized Operation Service Project" was also approved, pending shareholder meeting review [2][6] Group 2: Fundraising Replacement and Compliance - The board approved a proposal to use raised funds to replace previously invested self-raised funds for fundraising projects and issuance costs, which complies with regulatory requirements and does not affect the normal implementation of fundraising projects [4] - The accounting firm provided a verification report, and the sponsor also issued a no-objection opinion regarding this replacement [4][3] Group 3: Governance Structure and Management Optimization - The board approved the establishment of a "Director and Senior Management Compensation Management System," which will be submitted for shareholder meeting review [5] - A proposal to adjust the company's organizational structure for 2026 was also approved to further optimize the management system [5] Group 4: Upcoming Shareholder Meeting - The board decided to hold the first temporary shareholder meeting of 2026 on January 13, 2026, to submit the aforementioned proposals for shareholder voting [6] - The series of resolutions passed by the board reflects the company's emphasis on the standardized use of raised funds and strategic development, which will help optimize resource allocation and enhance core competitiveness [6]

Core Viewpoint - The Beijing Stock Exchange (BSE) is accelerating its IPO review process, with a focus on the sustainability and authenticity of company performance, as well as the necessity of fundraising projects [1][2]. Group 1: IPO Review Process - The BSE's listing committee held its 46th to 49th review meetings from December 22 to 26, 2025, approving four companies: Ying's Holdings, Longyuan Co., Puan Medical Technology, and New Hengtai New Materials, all meeting the issuance and listing requirements [1]. - Key concerns during the review included the sustainability of performance growth, accuracy of revenue recognition, reasons for declining gross margins, and the authenticity of online sales revenue [1]. Group 2: Company Performance - Ying's Holdings reported revenues of 1.296 billion yuan, 1.758 billion yuan, 1.974 billion yuan, and 1.132 billion yuan from 2022 to the first half of 2025, with net profits of 114 million yuan, 216 million yuan, 190 million yuan, and 136 million yuan [2]. - Longyuan Co. achieved revenues of 519 million yuan, 699 million yuan, 869 million yuan, and 475 million yuan during the same period, with net profits of 97 million yuan, 118 million yuan, 112 million yuan, and 61 million yuan [2]. - New Hengtai and Puan Medical also showed optimistic performance, with New Hengtai's revenues reaching 530 million yuan, 679 million yuan, 774 million yuan, and 384 million yuan, and net profits of 45 million yuan, 101 million yuan, 91.76 million yuan, and 51.35 million yuan [2]. Group 3: Quality of Companies in the Pipeline - As of December 25, 2025, there are 168 companies in the BSE's IPO queue, with only one company projected to be unprofitable in 2024, indicating an overall improvement in the quality of companies seeking to go public [4]. - Among the 168 companies, 50 have net profits exceeding 100 million yuan, accounting for 29.8% of the total [4]. - New companies entering the IPO process, such as Hubei Benxing New Materials, reported revenues of 3.726 billion yuan, 3.606 billion yuan, 4.445 billion yuan, and 2.287 billion yuan from 2022 to the first half of 2025, with net profits of 451 million yuan, 356 million yuan, 389 million yuan, and 199 million yuan [4].

根据北交所最新披露的信息，2025年12月26日，普昂（杭州）医疗科技股份有限公司IPO的状态从已问 询变更为通过。 根据北交所最新披露的信息，2025年12月26日，普昂（杭州）医疗科技股份有限公司IPO的状态从已问 询变更为通过。 ...

会上，顺博医疗、工大镀锌等区内重点科技企业代表，结合自身经营发展实际与数字化转型规划，详细介绍了企业现阶段发展状况及融资需求。 天津OTC、博正资本、鸿盛基金、天开执信等多家金融服务机构精准对接企业差异化需求，从股权融资、债权支持、产业链金融等多个维度，为企业量身 定制多元化资本支持方案。 为加快推进科技与金融深度融合，精准服务红桥区科技企业创新发展，强化科技企业融资对接实效，近日，在天津市科技局园区营商环境处指导下，红桥 区科技局、区科技创新发展中心聚焦区内企业融资痛点与发展需求，在三条石街道海河华鼎招商聚智厅组织召开"智慧办公 助力企业数字化转型"融资需 求对接会。 本次活动的成功举办，既是深入落实市、区科技创新工作联动机制的具体实践，也为区域科技型企业拓宽融资渠道、加快数字化转型注入了强劲动力。 会后，市、区两级科技部门还围绕党建共建、园区招商引智、区域科技成果转化、企业高质量发展等工作开展了深度交流研讨，为下一步协同推进区域科 技创新工作奠定了坚实基础。 今后，红桥区科技局将进一步创新服务模式、丰富对接内容、提高活动频次，搭建起科技企业与金融机构沟通协作的坚实桥梁，助力双方高效对接、深化 互信、共谋发 ...

Core Viewpoint - Yidu Technology has been invited to participate in the Henan Health Industry Development Conference and has signed on as one of the first partners of the National Artificial Intelligence Application Pilot Base (Medical Direction), marking a strategic expansion in the AI healthcare sector [1][3]. Group 1: Strategic Partnerships and Initiatives - The establishment of the National AI Application Pilot Base in Zhengzhou is a key initiative for Henan Province to implement national health strategies and develop the future health industry [3]. - Yidu Technology is collaborating with major tech companies like Baidu and Alibaba, as well as local medical institutions, to create a synergistic ecosystem that integrates technology, data, clinical applications, and AI in healthcare [3][4]. Group 2: Technological Capabilities and Innovations - Yidu Technology's proprietary "AI Medical Brain" YiduCore has processed nearly 7 billion authorized medical records, covering over 10,000 hospital partnerships, providing a solid foundation for AI model training and clinical insights [5]. - The company aims to leverage its experience in AI and data governance to support the integration of AI with traditional Chinese medicine, enhancing the quality of healthcare services in the region [4][5]. Group 3: Future Development and Goals - Yidu Technology plans to continue its focus on independent innovation and align its AI research and implementation with regional development needs, contributing to the "Healthy China 2030" initiative [5].

南方财经 21世纪经济报道记者胡慧茵 马来西亚槟城报道 在深厚的历史渊源下，多年来，槟城与广东在经贸、文化交往等多领域始终保持着紧密的联系，而近年来双方的投资合作更呈 现双向奔赴的态势。比如，今年10月，广东和槟城共8个单位在投资推介会上签署了多项备忘录与合作协议，进一步促进两地在 商贸与投资领域的交流与合作关系。 近日，马来西亚槟城州首席部长曹观友在接受21世纪经济报道记者专访时表示，槟城与广东的产业有非常明显的互补性，广东 创新能力强，在芯片设计、工业互联网、人工智能、新能源、生物医药及数字经济等领域发展迅速，而槟城在半导体封测、工 业自动化、精密工程、医疗器械制造和高端电子制造方面积累深厚，"这种'设计强 + 制造强'的组合，为双方共同推动跨区域产 业链布局提供强劲动力。" 近年来，马来西亚槟城也成了中企"出海"热潮的目的地。今年10月底，中国企业联特科技二期工厂在槟城开幕，成为中企扎根 当地的典型案例。"从2021年至今，槟城共获得78项来自中国的制造业投资，总额达到168亿林吉特，这反映中国企业对槟城产 业环境与增长潜力的高度认可。"曹观友进一步表示，未来中马有望在人工智能芯片、新能源电池、储能系统 ...

经营范围含一般经营项目是：医院管理；健康咨询服务（不含诊疗服务）；技术服务、技术开发、技术 咨询、技术交流、技术转让、技术推广；第二类医疗器械销售；第一类医疗器械销售；眼镜销售（不含 隐形眼镜）；软件销售；食品销售（仅销售预包装食品）；保健食品（预包装）销售；会议及展览服务 （出国办展须经相关部门审批）；信息技术咨询服务；互联网销售（除销售需要许可的商品）。（除依 法须经批准的项目外，凭营业执照依法自主开展经营活动），许可经营项目是：第三类医疗器械经营； 第三类医疗器械生产；第二类医疗器械生产；生活美容服务；药品零售；互联网新闻信息服务；药品互 联网信息服务；食品销售。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项 目以相关部门批准文件或许可证件为准） 企业名称深圳爱目医疗科技有限公司法定代表人朱奕冰注册资本5000万人民币国标行业卫生和社会工作 >卫生>医院地址深圳市南山区粤海街道科技园社区科苑路16号东方科技大厦1895企业类型有限责任公 司(法人独资)营业期限2025-12-25至无固定期限 来源：市场资讯 天眼查显示，近日，深圳爱目医疗科技有限公司成立，法定代表人为朱奕冰，注册资本 ...

Core Insights - The article highlights the vibrant innovation and entrepreneurial spirit in Shenyang, where local entrepreneurs are actively working on technological breakthroughs and product developments for the future [3][8]. Group 1: Company Innovations - Shenyang Jinran Technology Co., led by CEO Ran Jinchuan, has developed a "MR Science Experiment Course System" that transforms classroom experiences in multiple schools across Liaoning, making dangerous experiments safe and abstract theories visual [4][6]. - Liaoning Ruiyi Technology, founded by Qiu Zhaowen, focuses on using artificial intelligence for early screening and treatment of cardiovascular diseases, aiming to become a "super assistant" for doctors, especially in resource-scarce areas [6][7]. Group 2: Educational Integration - Dong Yingnan, a vice professor at Shenyang Engineering College, emphasizes the importance of "industry-education integration," where students participate in real-world projects, enhancing their practical skills [5][6]. - The collaboration between local universities and companies is seen as a way to cultivate talent that understands both theoretical principles and practical applications, contributing to the city's industrial upgrade [6][7]. Group 3: Future Aspirations - The entrepreneurs express a strong desire to expand their innovations beyond Shenyang, with goals such as national distribution of their products and deeper collaborations with local hospitals [4][6][7]. - The article concludes that the entrepreneurial efforts in Shenyang are not just about individual success but are part of a larger narrative of the city's industrial and technological evolution [7][8].

中新网北京12月25日电(记者 赵方园)"一切医学研究，出发点是病人、源于临床，最后回到生态体系， 在这三个层次上继续形成反哺，这就是我们的发展思路。"近日，在第二届海医汇医疗科技创新生态大 会上，中国工程院院士、中国医学科学院血液病医院(中国医学科学院血液学研究所)院长程涛表示，医 疗行业、大健康产业的成功离不开"政、产、学、研、用"组成的组合拳。 良好的平台与高质量的数据是医疗科技创新的两大基石。中国工程院院士、中国医学科学院血液病医院 (血液学研究所)院长程涛指出，一个优越的创新平台与氛围，能极大释放科研人员的独特思想与研发能 力。 中国医学科学院医学信息研究所所长刘辉提出，让医疗数据"流得通、用得好"需从三方面着力：一是推 进数据标准化与质量治理，实现跨机构、跨模态数据的语义对齐；二是建立全流程可控、技术保障的数 据流通机制，在保障安全与权属前提下释放价值；三是将数据深度融入医学知识体系，构建面向AI应 用的高可信度数据基座。 大会聚焦了由临床迫切需求驱动的尖端科技探索。国家神经疾病医学中心主任、首都医科大学宣武医院 院长赵国光从临床视角深入剖析了脑机接口技术。他指出，针对渐冻症、脊髓损伤等难治性神经 ...

瑞财经 刘治颖 近日，上海英捷信医疗科技有限公司（以下简称"英捷信医疗"）已成功完成数千万元人 民币A+轮融资，本轮融资由毅达资本独家投资，浩悦资本担任独家财务顾问。本轮资金将用于进一步 扩大全球高质量标准的产能体系建设，拓展全球营销与注册团队。 英捷信医疗成立于2021年9月，系一家致力于自我给药系统研发及制造的医疗科技企业。公司目前在售 产品为多款适配胰岛素、GLP-1、生长激素、促卵泡素等生物制剂的高精度笔式注射装置。 天眼查显示，英捷信医疗实际控制人为吴亚金，总持股比例为22.03%，表决权为24.64%。目前，吴亚 金担任公司董事长。 公司总部位于上海，并在江苏无锡设有超10000平米产业化工厂，配套有十万级净化组装车间以及密闭 组装车间。同时公司拥有独立模具加工工厂及零部件注塑工厂，可实现皮下给药装置从设计开发、模具 加工、注塑成型到产品规模化组装的一体化、全流程配套生产服务。截。 ...